



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/524,454	03/10/2000	Kristian Berg	697.013US1	5804
21186 7590 01/28/2010 SCHWEGMAN, LUNDBERG & WOESSNER, P.A. P.O. BOX 2938 MINNEAPOLIS, MN 55402				
EXAMINER EWOLDT, GERALD R				
ART UNIT 1644		PAPER NUMBER		
NOTIFICATION DATE 01/28/2010		DELIVERY MODE ELECTRONIC		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

[uspto@slwip.com](mailto:uspto@slwip.com)  
[request@slwip.com](mailto:request@slwip.com)

**Office Action Summary****Application No.**

09/524,454

**Applicant(s)**

BERG ET AL.

**Examiner**

G. R. Ewoldt, Ph.D.

**Art Unit**

1644

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 15 January 2010.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 2, 4, 8-10, 28-32, 37 and 41 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 2, 4, 8-10, 28-32, 37 and 41 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SE/C.3)
- 4) ☐ Interview Summary (PTO-413)
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_
- Paper No(s)/Mail Date \_\_\_\_\_

#### DETAILED ACTION

1. A request for continued examination (RCE) under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed 1/15/10 in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's amendment and remarks filed 1/15/10 have been entered.
2. Claims 2, 4, 8-10, 28-32, 37 and 41 are pending and being acted upon.
3. Upon reconsideration, and in view of Applicant's amendments and remarks, the previous rejection under the first paragraph of 35 U.S.C. § 112 has been withdrawn. In particular, the routine and well-known nature of photochemical internalization at the time of the invention, as exemplified in WO 96/07432, would have allowed the skilled artisan to perform the claimed method without undue experimentation.
4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --  
(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
5. Claims 2, 4, 8-10, 28-32, 37 and 41 stand/are rejected under 35 U.S.C. 102(b) as being anticipated by WO 96/07432 (IDS).

As set forth previously, WO 96/07432 teaches a method of expressing [now presenting an antigenic molecule on the surface of a viable cancer cell, said method comprising:

contacting said cell *in vitro* [and *ex vivo*] with said antigenic molecule [now peptide] (including a vaccine component, a molecule capable of stimulating an immune response, and a peptide, also including an antigen bound to a carrier molecule) and with a photosensitizing agent (a porphyrin, phthalocyanine, purpurin, chlorin, benzoporphyrin, naphthalocyanine, cationic dye, and tetracycline, including TPPS<sub>1</sub>, TPPS<sub>2a</sub>, and AlPcS<sub>2a</sub>, also including a photosensitizing agent bound to a carrier molecule), wherein said molecule and said agent are each taken up into an intracellular membrane-restricted compartment of said cell; and irradiating said cell with light of a wavelength effective to

Art Unit: 1644

activate the photosensitizing agent, such that the membrane of said intracellular compartment is disrupted, releasing said molecule into the cytosol of the cell, without killing the cell by irradiation, wherein, said released antigenic molecule, or a part thereof of sufficient size to generate an immune response, is subsequently presented on the surface of said cell by a class I MHC molecule (see particularly the claims). Note that reference does not specifically state that the method results in the cell surface expression of the antigen in MHC Class I, however, the reference teaches the same steps as those of the instant claims, thus, said same steps would inherently result in the same outcome, i.e., the claimed method of the expressing an antigenic molecule on the surface of a viable cell. The reference further teaches the *in vivo* administration of and antigen and photosensitizing agent (page 6), thus, Claim 37 has been included in the rejection.

Applicant's arguments, filed 1/15/10 have been fully considered but they are not persuasive. Applicant argues that the reference teaches only the internalization of toxins into cancer cells.

As set forth previously, the reference is clearly not limited to the internalization of toxic molecules, nor to gene therapy nor to *in vitro* internalization, i.e., the exemplified embodiments as Applicant argues. The three methods at pages 7-8 are disclosed only as "Examples of experimental and clinical utilization". Further, see for example Claim 2 wherein the internalized compounds include, "sugars, proteins, and peptides", none of which are required to be toxic and all of which can be antigens depending on the context. Indeed, at page 2 (as well as in the Abstract) of the reference it is taught that the method is performed, without destroying the functionality of the majority of the cells." After the release of the internalized compound into the cytosol of a live cell processing and presentation on MHC class I would be an inherent property.

Further, a review of the instant specification discloses at page 4:

"WO 96/07432, on the other hand, is concerned with methods which use the photodynamic effect as a mechanism for introducing otherwise membrane-impermeable molecules into the cytosol of a cell in a manner which does not result in widespread cell destruction or cell death. In this method, the molecule is co-internalised (more particularly, "endocytosed") into an intracellular vesicle in the cell (e.g. a lysosome or endosome) together with a photosensitizing agent. The cell is then exposed to photoactivating light which "activates" the photosensitizer, which in turn causes the vesicle membrane to disrupt or rupture, releasing the vesicle contents, including the molecule, into the cell interior i.e. the cytosol. It was found that in such a method the functionality or the viability of the majority of the cells was not deleteriously affected. Thus, the utility of such a method, termed, "photochemical internalization" was proposed for

Art Unit: 1644

transporting a variety of different molecules, including therapeutic agents, into the cytosol i.e. into the interior of a cell".

And at page 12 the specification discloses:

"The photochemical internalization process is described in more detail in WO 96/07432 (the contents of which are incorporated herein by reference). Methods of PDT are now widely described in the literature."

Clearly, at the time of the invention, Applicant's viewed the teachings of the WO document as broader than they now argue.

Applicant argues that the reference only teaches cancer cell death.

The reference clearly teaches the introduction of molecules into cells without killing them. The reference also teaches the introduction of molecules into cancer cells. Thus, the reference anticipates the method of the instant claims.

Applicant argues that the reference fails to disclose expression or presentation of the antigenic peptides on the cell surface.

The reference teaches the method of the instant claims. Therefore, the outcome of said method must be the same, i.e., expression or presentation of the antigenic peptides on the cell surface is inherent.

6. The following is a new rejection necessitated by Applicant's amendment.

7. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8. Claim 41 is rejected under 35 U.S.C. 112, first paragraph, as the specification does not contain a written description of the claimed invention, in that the disclosure does not reasonably convey to one skilled in the relevant art that the inventor(s) had possession of the claimed invention at the time the application was filed. This is a written description

rejection for the introduction of new matter into the claims.

The specification and the claims as originally filed do not provide support for the invention as now claimed, specifically:

A) a method... wherein the antigenic peptide stimulates proliferation of cytotoxic T cells.

The specification at page 10 discloses proliferation of cytotoxic T cells only after stimulation with *foreign* antigens.

9. No claim is allowed.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, Ph.D. can be reached on (571) 272-0878.

11. **Please Note:** Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

/G.R. Ewoldt/  
G.R. Ewoldt, Ph.D.  
Primary Examiner  
Technology Center 1600